Form 4: Cullinan Therapeutics Director Anthony Rosenberg Receives Significant Stock Option Grant

Cullinan Therapeutics, Inc. Director Anthony Rosenberg was granted options to purchase 38,513 shares of common stock at an exercise price of $8.95, aligning his interests with shareholder value.

Summary

• Anthony Rosenberg, a Director of Cullinan Therapeutics, Inc. (CGEM), was granted stock options to acquire 38,513 shares of the company's common stock.
• The options have an exercise price of $8.95 per share.
• The grant date for these options was June 12, 2025.
• The options are set to vest in full on the earlier of June 12, 2026, or the date of the Issuer's next annual meeting, contingent on Mr. Rosenberg's continued service as a director.
• The expiration date for these stock options is June 12, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (option grant) which is generally viewed as neutral to slightly positive as it aligns director interests with shareholders, but does not contain significant new financial or operational information to warrant a strong sentiment.

Positives

• The grant of stock options to Director Anthony Rosenberg aligns his financial interests directly with the long-term performance and shareholder value of Cullinan Therapeutics, Inc.
• The vesting schedule encourages continued service and commitment from a key board member.

Future Outlook

The stock options granted to Director Anthony Rosenberg are subject to a vesting schedule, which will occur in full on the earlier of June 12, 2026, or the date of the Issuer's next annual meeting, provided he continues his service as a director.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation to align the interests of board members with those of shareholders.

Related Party Transactions

• The grant of stock options to Anthony Rosenberg, a director of Cullinan Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders if the stock price increases.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest on the earlier of June 12, 2026, or the date of the Issuer's next annual meeting, subject to Anthony Rosenberg's continued service as a director.
• Following vesting, Anthony Rosenberg will have the right to exercise these options to purchase common stock at the specified exercise price until the expiration date of June 12, 2035.

Key Dates

Keywords

Cullinan Therapeutics, CGEM, Anthony Rosenberg, Stock Option, Insider Transaction, SEC Form 4, Director Compensation, Equity Grant, Beneficial Ownership